Stephens initiated coverage of MaxCyte (MXCT) with an Overweight rating and $6 price target The company is in the early stages of making prudent investments in offerings that expand its reach of the market, the analyst tells investors in a research note. The firm added that while this strategy is still in the early innings, it believe the strategy has the potential to drive long-term revenue growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MXCT: